Patients With Relapsed Large B-Cell Lymphoma After 12 Months Have a Similarly Poor Prognosis to Those Relapsing Within 12 Months.

ABSTRACT: Chimeric antigen receptor T-cell therapy (CART) has replaced salvage immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (HDT-ASCT) as the preferred second-line treatment for early relapsed (< 12 months) large B-cell lymphoma (LBCL). However, for patients with a late relapse (> 12 months), CART is inaccessible until third line. We analyzed 877 patients from the HemoBase registry (diagnosed 2005-2020) to assess differences in long-term outcomes of early versus late relapse in second line. Early relapse occurred in 120/654 patients (18%) who completed first-line treatment, with 2- and 5-year overall survival (OS) of 22% and 18%. Late relapse occurred in 70 patients (11%), showing slightly better 2-year OS of 36% but similarly poor 5-year OS of 20%.

SUBMITTER: van der Galien HT 

PROVIDER: S-EPMC12402851 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature